If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

By Rick Winterson  Vertex Pharmaceuticals is a worldwide biotechnology corporation. It was founded 35 years ago in Cambridge.  It has now established its global headquarters on Fan Pier in South ...

Plus: A new non-opioid painkiller, the wave of lawsuits against Trump EOs, a key vote for RFK Jr., a big radiopharma deal and more.

USAID staffers told stay out of D.C. headquarters ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

Vertex Pharmaceuticals Incorporated (Nasdaq ... Patients may report side effects to the FDA at 1-800-FDA-1088. Vertex is a global biotechnology company that invests in scientific innovation to create ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company will ...

Notably, Vertex Pharmaceuticals (NASDAQ: VRTX), which focuses on developing treatments for rare diseases, has significantly outpaced both its biotechnology peers and the S&P 500 since early 2022.